<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110999">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01959165</url>
  </required_header>
  <id_info>
    <org_study_id>D5172C00001</org_study_id>
    <nct_id>NCT01959165</nct_id>
  </id_info>
  <brief_title>MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, randomised, double-blind, placebo controlled, parallel group, Phase
      II study to evaluate efficacy and safety of 3 doses of MEDI7183, in Japanese subjects with
      moderate to severe UC
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Remission rate</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Remission rate defined as a total Mayo Score ≤ 2 points, and with no individual subscore &gt; 1 point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response rate assessed by total Mayo score.  Response is defined as decrease ≥ 3 points and 30% in total Mayo Score compared to baseline (Visit 1), and with an accompanying decrease in the subscore for rectal bleeding of ≥1 point or with an absolute subscore for rectal bleeding of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal healing rate</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mucosal healing rate at Week 8 defined as an absolute Mayo subscore for rectosigmoidoscopy of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate assessed by PMS</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response at Week 12 assessed by PMS. Response is defined as reduction by ≥2 points and 25% in PMS compared to baseline (Visit 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and torelability assessed by adverse event rate etc</measure>
    <time_frame>0-76 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, serious adverse events, discontinuations of investigational product due to adverse events (DAEs), laboratory values and vital signs through 28 weeks after last dose of MEDI7183</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics assessed by Serum concentration</measure>
    <time_frame>0-76 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics assessed by Receptor Occupancy and memory CD4 α4β7 hi cell numbers</measure>
    <time_frame>0-12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Receptor Occupancy and memory CD4 α4β7 hi (CD4 circulating lymphocytes expressing high levels of α4β7-integrin) cell numbers over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti- MEDI7183 antibodies</measure>
    <time_frame>0-76 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Anti- MEDI7183 antibodies</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mayo score</measure>
    <time_frame>0-76 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total Mayo Score and Partial Mayo Score at each assessment, and individual Mayo sub-score (ie, stool frequency, rectal bleeding, rectosigmoidoscopy, physician's global assessment) at each assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>C-Reactive Protein</measure>
    <time_frame>0-76 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in CRP at selected time points</description>
  </other_outcome>
  <other_outcome>
    <measure>PK/PD</measure>
    <time_frame>0-76 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Exposure-response relationship for efficacy as measured by the total Mayo and Partial Mayo Score</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient perception of change in disease</measure>
    <time_frame>0-12 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient perception of change in disease, as measured by Patient Global Rating of Change</description>
  </other_outcome>
  <other_outcome>
    <measure>IBDQ</measure>
    <time_frame>0-12 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Inflammatory Bowel Disease Questionnaire total score and subscores from the 4 sub-domains: Bowel symptoms, systemic symptoms, emotional function, and social function</description>
  </other_outcome>
  <other_outcome>
    <measure>UCPRO module 1 - 3</measure>
    <time_frame>0-12 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bowel movements, symptom severity and coping activities as measured by the Ulcerative Colitis Patient Reported Outcome (UC PRO) modules 1-3.</description>
  </other_outcome>
  <other_outcome>
    <measure>UCPRO module 4 &amp; 5</measure>
    <time_frame>0-12 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Emotional impact and impact on daily life as measured by the UC PRO modules 4 and 5</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>MEDI7183 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blinded</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7183 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blinded</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7183 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blinded</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double blinded</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI7183 low dose</intervention_name>
    <description>MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8</description>
    <arm_group_label>MEDI7183 dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI7183 medium dose</intervention_name>
    <description>MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8</description>
    <arm_group_label>MEDI7183 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI7183 high dose</intervention_name>
    <description>MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8</description>
    <arm_group_label>MEDI7183 dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Placebo will be administered by SC on Day 1, Week 2,4, and 8</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Diagnosis of UC established by clinical and endoscopic evidence and corroborated by a
             histopathology report

          -  Moderate to severe active UC as defined by a total Mayo score of 6 to 12 with
             rectosigmoidoscopy score ≥ 2 during screening period

          -  Demonstrated an inadequate response to, loss of response to, or intolerance to at
             least one of immunomodulators or Anti- TNF-α agents.   etc.

        Exclusion Criteria:

          -  Disease limited to the rectum

          -  Toxic megacolon

          -  Crohn's Disease

          -  History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch,
             Koch pouch, or ileostomy for UC

          -  Planned bowel surgery within 12 weeks from Visit 2

          -  Stool positive for C. difficile toxin at screening

          -  Primary Sclerosing Cholangitis

          -  History of gastrointestinal surgery within 8 weeks of Visit 2

          -  Any uncontrolled or clinically significant systemic disease

          -  Condition or disease that, in the opinion of the investigator would pose a risk to
             subject safety or interfere with study evaluation, procedures or completion

          -  Subjects with positive HBsAg, HBsAb, HBcAb or HCVAb serology at screening etc
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshifumi Hibi, Director and Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masataka Date, Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>AztraZeneca, Osaka, Japan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kanetoshi Washio</last_name>
    <phone>+81 6 6453 7356</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Masataka Date, MD</last_name>
    <phone>+81 6 6453 8023</phone>
    <email>Masataka.Date@astastrazeneca.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chikushino-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujiidera-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fushimi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamamatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kamakura-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meguro-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niigata-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nishinomiya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakura-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takatsuki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokkaichi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis, Japanese, subcutaneously</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
